TECHNOLOGY OFFER

HIERRIDIN C AS ANTIMALARIAL AND ANTICANCER AGENT

Background

Malarial drug-resistant strains are emerging worldwide, in particular mefloquine and chloroquine-resistant, becoming a significant concern on a global scale.
There is a growing need for antimalarial agents for monotherapy or multi-drug therapies. Therefore, new agents able to kill the resistant malaria parasites are warranted.

Technology

This technology relates to new halogenated alkyl-aromatic secondary metabolites, obtained from *Cyanobium* sp. (LEGE 06113), hierridin C, and its derivatives and their use as antimalarial and anticancer agents.
This technology comprises methods for obtaining the compound from cyanobacterial cultures and methods for chemically synthesizing hierridin C and its derivatives under laboratory conditions.
The solution herein relates to compounds sharing the same halogenated skeleton as hierridin C, and to its use in formulations for treating, preventing, or inhibiting malaria in humans.



Advantages

- Effective against drug-resistant *P. falciparum*;
- New mechanism of action;
- Hierridin C is a natural product obtainable by mass culturing in the lab or open pounds; alternatively it can be chemically synthesized;
- Low toxicity;
- The compound/compositions can be administered by various routes in the context of veterinarian and human medicine.

PATENT STATUS

International Patent Application via PCT WO2016207869
Priority date: 25.06.2015
Granted in Europe, US, Brazil and India

DEVELOPMENT STAGE

TRL4 – Technology validated in lab
Further development for validation in large scale setups required.

APPLICATIONS

Malaria treatment;
Anticancer treatment;
Pharmaceutical.

COOPERATION

Licensing agreement;
Product development;
Implementation of the antimalarial drug discovery pipeline.

KEYWORDS

hierridin C
Halogenated alkyl-aromatic
Antimalarial
Anticancer

DEVELOPED BY

CIIMAR - Centro Interdisciplinar de Investigação Marinha e Ambiental;
Instituto de Higiene e Medicina Tropical;
Instituto Politécnico do Porto
Universidade do Porto.

techtransfer@ciimar.up.pt